Sabarish Ayyappan MD

This is huge , will help with cost savings for our myeloma patients.

I am a hematologist and physician–scientist involved in the treatment and research of blood cancers, with a background in basic science laboratory work. While my publication record is publicly accessible, I do not consider myself an “expert” in the way the term has often been loosely applied—particularly since the COVID-19 era, when individuals with limited scientific rigor were frequently elevated as authorities despite being a doctor specializing in a totally different specialty. I appreciate your willingness to address pseudoscience, especially in circumstances where many of us lacked the time or platform to respond. I felt compelled to raise some professional concerns regarding Dr. Pal. Although he has publicly presented himself as a gastroenterologist with an academic flavor on gut microbiome, his scholarly record does not reflect sustained independent academic output. There appear to be few, if any, first-author publications since approximately 2013. Earlier publications were largely co-authored during fellowship training, which is typical at that stage but does not, in itself, support later claims as an expert with ongoing academic contribution. Publicly emphasizing awards for “academic excellence” in a way that may mislead lay audiences is concerning. During the COVID-19 pandemic, Dr. Pal also stated publicly that he treated large numbers of COVID patients. These claims seemed difficult to reconcile with gastroenterology practice patterns in the United States at that time, when elective procedures were largely suspended and non-urgent clinical activity was significantly curtailed. Much of his public commentary during this period appeared to rely on fear-based messaging rather than careful, evidence-driven interpretation of emerging data as the science still continues to evolve around COVID. Dr. Pal has also publicly expressed the view that studying and practicing medicine in India is effectively unattainable for first-generation physicians who do not come from families that own hospitals. This characterization is inaccurate and overly reductive. I trained in India, as did many colleagues who are first-generation physicians and have gone on to achieve professional distinction through merit, academic effort, and public service. My own ongoing, collegial collaborations with physicians in India, including philanthropic work focused on patient education and cancer care, further underscore that the Indian medical system, while imperfect, is neither closed nor inferior. Last but not the least, Dr. Pal’s rise in public prominence also followed the circulation of a widely shared video in which he made derogatory remarks about the acting abilities of Vikram Prabhu, a prominent figure in Tamil cinema. That episode appeared to play a substantial role in increasing his visibility. It is therefore notable that he now engages openly within the same entertainment industry, which raises reasonable questions about consistency, professional judgment, and the possibility of fame-seeking motivations. While some of his earlier work in instagram was probably done with a good intent, he has failed to recognize where the lines of his expertise are. At a time when scientific rigor, transparency, and public trust were particularly critical, these patterns warrant thoughtful scrutiny and responsible discussion within the medical community.

Baier: What do you say to folks who want to know a total number of all these investments that the president is bringing in… Do you have a total number? Bessent: Well, the president uses the number 20 trillion in terms of total investments and I think that those commitments are real.

After a woman reporter asked about President Trump’s name being raised in emails sent by convicted sex offender Jeffrey Epstein, Trump snaps at her: “Quiet, piggy!” Disgusting and completely unacceptable. cnn.com/2025/11/18/us/…

@Myeloma_Doc Thx for highlighting Dr. Orlowski. Seems to be dose intensity related and stopping the drug reverses it

If you are in LA and please join us to raise funds for myeloma research. The contribution to research always improves quality of people's lives in the future and discovers new therapies. My personal goals are to CURE MM and mitigate side effects of treatments. Let's walk towards the goals ....@IMFmyeloma @IMFsupport @IMFjimMYELOMA

We are near and have good speakers...

Incredibly proud of this groundbreaking CAR-T therapy research from @hkJain_kmc @ManjuSengar7 @purwarrahul2 @DrGauravNarula and others at @TataMemorial @ACTREC_TMC @iitbombay that demonstrates what the outcomes can be when meaningful collaborations happen thelancet.com/journals/lanha…

We need a better team to match this endeavor ⁦@Abdallah81MD⁩ ⁦@ZanwarSaurabh⁩ ⁦@ManUtd⁩

Cub Paw winners of the week! Great work friends!

linkedin.com/posts/sabarish… @AJMC_Journal @cityofhope

We recently published a review on Economics and cost effectiveness of drugs in Multiple myeloma. This is important if we want to reduce disparities and global access. Open access paper- rdcu.be/d6QjP @praneethkeesari @CharanVegivinti

@Abdallah81MD @ZanwarSaurabh If we don't get relegated it's an achievement for rest of the season 😂

I was wrong @ZanwarSaurabh @SabarishMD

This is true fergie time @ManUtd @Abdallah81MD @ZanwarSaurabh @gaurang53

Impressive fightback by our lads @ManUtd @Abdallah81MD @ZanwarSaurabh

@Abdallah81MD @ManUtd @LFC Hope you made it safe , good to draw level with @LFC , have some kops riled up aka @JanakiramMurali

Let's see if I can make it back to watch @ManUtd vs @LFC 🥶

@Abdallah81MD @ZanwarSaurabh Felt like a deflated balloon today , hoping for a miracle to get out of the bottom , I never imagined we would be here !

I got nothing to say! @SabarishMD @ZanwarSaurabh anything U want to add?

Very disappointing display @abdallah81md @ manutd

@Abdallah81MD @ManUtd Another fergie time win, hope this winning mentality continues !

Unbelievable we won 🤯🤯🤯🤯 @ManUtd Manchester is Red today

With durable response rates and positive QOL outcomes, odronextamab could transform therapeutic approaches for these challenging lymphomas, especially for patients with limited options. #lymsm | @Tessoulin_B @cityofhope @SabarishMD targetedonc.com/view/does-odro…